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Abstract
Alzheimer’s disease (AD) is one of the most common types of neurodegenerative disease. There
are currently no treatment methods for AD, but there are treatments for some of the symptoms.
Aberrant levels of both O-GlcNAcylation and GSK3ß have been found in patients with AD.
Studies have suggested that there is a relationship between the level of O-GlcNAcylation and the
phosphorylation of GSK3ß. In order to discover new treatment methods, the phosphorylation of
GSK3ß should be explored. This study uses a western blot analysis to quantify the ratio of pGSK3ß:GSK3ß between the experimental group (higher levels of O-GlcNAcylation) and a
control group. The preliminary results suggested that there was no significant difference in the
phosphorylation of GSK3ß when the levels of O-GlcNAcylation are increased.
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Introduction
Alzheimer’s disease (AD) affects 11.3% of people older than 65.1 AD primarily affects
the hippocampus, the brain region that is involved in learning and memory.2 The two hallmarks
of AD are neurofibrillary tangles and neuritic plaques.3 Although there are no effective treatment
methods for AD, there are therapies to treat the symptoms.4
In order to develop more effective options for the treatment of AD, additional research is
needed to understand the mechanism associated with the development of AD. There are aberrant
levels of O-GlcNAcylation and GSK3β in AD. Also, recent studies have shown that OGlcNAcylation and GSK3β are competitive inhibitors. Additional research should be conducted
in order to elucidate the relationship between O-GlcNAcylation and GSK3β.
Researchers are using murine models to better understand AD and the role of OGlcNAcylation. Due to the complete knockout of O-GlcNAcase (OGA) being embryonic lethal,
OGA must be manipulated post the birth of the mouse. Therefore, researchers are using a TetOff system. This inhibits the transcription of OGA by the administration of doxycycline.
The purpose of this study is to evaluate the effects of the increased level of OGlcNAcylation on the phosphorylation and transcription of GSK3β. The analysis of Western
blots will be used to compare the levels of p-GSK3β and GSK3β between mice with differing
levels of O-GlcNAcylation. Also, the total level of GSK3β compared to actin will be observed.
This research is attempting to answer the following questions:
•

Is the ratio of p-GSK3β:GSK3β significantly affected when the levels of OGlcNAcylation are increased?

•

Is the total level of GSK3β is significantly affected when the levels of OGlcNAcylation are increased?
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Understanding these answers will allow for a better explanation of the relationship between OGlcNAcylation and GSK3β.

3
Review of Literature
Alzheimer’s Disease
Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases, along
with Parkinson’s disease and amyotrophic lateral sclerosis.1 Neurodegeneration refers to the
decline in neuronal function, which results from cell death.5 In AD, the neurons within the
hippocampus are particularly susceptible to damage. This decline in the function of neurons
results in the impairment of memory, reasoning, language, and judgment.6
Dementia is a term used to describe the symptoms associated with a decline in cognitive
ability.7 AD is the most prevalent type of dementia, accounting for more than two-thirds of all
dementia patients.6 Dementia impedes a person’s ability to perform independent, daily
activities.7

Epidemiology
AD is prevalent in patients who are older than 65-years-old.6 One of the most widespread
risk factors for AD is an increase in age.6 However, AD is not a normal aspect of aging.6 Lateonset is the most common type of AD case.8 Due to the age-dependent nature of the AD, it is
becoming more prevalent partly due to the recent increase in the elderly population.9 Other risk
factors for AD include depression, higher parental age, family history of dementia, smoking,
cardiovascular disease, diabetes, head trauma, and others.6
Hallmarks of AD are neurofibrillary tangles and neuritic plaques (Figure 1).6
Neurofibrillary tangles are found within neurons.6 In patients with AD, there is an increase in the
phosphorylation of tau, which results in fibrillary intracytoplasmic structures.6 They form
insoluble paired helical filaments, which are referred to as neurofibrillary tangles. 6 These tangles
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interfere with the normal function of the cells.6 Neuritic plaques are found at axonal endings, and
they are tiny lesions containing extracellular amyloid beta-peptides.6 They are a result of the
breakdown of amyloid precursor proteins, which is why they are also known as amyloid
plaques.10 Both neurofibrillary tangles and neuritic plaques lead to neuronal cell death.6

3

Figure 1 Neurofibrillary tangles and neuritic plaques 3

Current Treatment Methods
In the United States, AD is the sixth leading cause of death.6 More than 5.8 million
Americans were suffering from AD in 2020, and this number is predicted to increase to 14
million Americans by 2060.11 Although there are available treatments for some symptoms, there
is currently no cure for AD.6 The symptomatic treatments target the neurotransmitter imbalance,
and they attempt to counteract it.4 A few studies have suggested that preventative/therapeutic
approaches would be beneficial for delaying the age at onset, but there have been no successful
therapies discovered.12
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Brain and Hippocampus
Central Nervous System
The nervous system is split into the central nervous system (CNS) and the peripheral
nervous system (PNS).13 The CNS is composed of the brain and spinal cord, and the other parts
of the nervous system make up the PNS.13 The CNS is a complex network that detects
environmental stimuli and allows interaction between the organism and its surroundings. 13 The
brain regulates the processes of the body, including movement, cognition, breathing, etc.13 The
brain is also responsible for memory, emotions, and communication.14
This study will focus on the brain, which is a part of the CNS. The brain is comprised of
nervous tissue, which is very delicate.14 Nervous tissue is composed of neurons and glial cells.15
Although there are more glial cells than neurons, they take up an equal amount of space within
nervous tissue. Glial cells function to support and protect neurons.16 In the CNS, astrocytes and
oligodendrocytes are the main types of glial cells.15 Astrocytes surround the body of neurons.16
Astrocytes assist in the migration of neurons and aid in detoxification.16 Astrocytes also form the
blood-brain barrier.16 Additionally, astrocytes manage synaptic transmission.16 The primary
function of oligodendrocytes is to generate myelin sheath.16 Myelin sheath surrounds nerves and
acts as an insulator which allows for the fast and efficient transmission of electrical impulses.16
Due to the importance of the brain, it is protected by the skull, meninges, and cerebrospinal
fluid.14 Also, the blood-brain barrier blocks harmful substances from entering the brain via the
blood.14

Neurons
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Neurons are comprised of a soma (cell body), dendrites, an axon, and an axon terminal.17
The nucleus and other essential organelles are housed in the cell body.17 The dendrites receive
afferent signals from their environment and other neurons; they are considered the “ears” of the
neuron.17 Most neurons have multiple dendrites, which allows them to receive multiple signals
simultaneously.18 Neurons only have one axon.18 The axon sends efferent signals to other
neurons, and it is considered the “mouth” of the neuron.17
A neuron is a cell that can be electrically excited.18 Neurons send signals all over the
body.18 Neurons interact with other neurons through the synaptic cleft, the space between the
presynaptic neuron’s axon terminal and the postsynaptic neuron’s dendrite.18 The information is
transmitted through both electrical and chemical components.18
Once a dendrite is stimulated, an electrical signal is sent to the soma.19 The soma contains
the axon hillock, which controls neuronal firing.19 If the combined signal strength is greater than
-40 mV, the threshold limit, a signal will be fired.19 This signal is known as an action potential.19
The electrical signal is sent down the axon by a depolarizing current.19
The first stage of the action potential occurs when voltage-gated sodium channels
(VGNaC) open and sodium ions rush into the cell.20 The increase of positive ions leads to the
depolarization of the cell, and this leads to a positive-feedback cycle of more VGNaC opening.20
After 1 msec, the depolarization of the neuron ceases and the VGNaC become inactive.20 The
second stage that takes place is repolarization.20 This occurs when voltage-gated potassium
channels (VGKC) open and potassium ions flow out of the cell.20 This allows for the cell to
return to its resting membrane potential (RMP), -70 mV.20 The final stage of the action potential
is termed hyperpolarization.20 This refers to the short period when the membrane potential is
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lower than the RMP, due to the VGKC being open a little longer.20 The action potential beings at
the axon hillock, and it travels down to axon to the axon terminal.20

Figure 2 Representative graph of an action potential 21
Once the action potential reaches the axon terminal, it triggers the opening of voltagegated calcium channels.22 This leads to an influx of the flow of calcium into the presynaptic
neuron.22 The increase of calcium causes the vesicles filled with neurotransmitters to dock on
and fuse with the plasma membrane.22 The neurotransmitter is then released into the synaptic
cleft and binds to receptors on the postsynaptic neuron.22 This produces a signal in the
postsynaptic neuron.22
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Figure 3 Communication between pre- and postsynaptic neurons23
Neurotransmitters can excite, inhibit, or modify the target tissue.22 A few excitatory
neurotransmitters are glutamate, acetylcholine, histamine, and norepinephrine.22 These
neurotransmitters cause the neuron to be depolarized, increasing the chance of propagating an
action potential.22 A couple of inhibitory neurotransmitters are gamma-aminobutyric acid
(GABA) and serotonin.22 These neurotransmitters cause the neuron to be hyperpolarized,
decreasing the chance of firing an action potential.22 Other types of neurotransmitters are
neuromodulators and neurohormones.22

Synaptic Plasticity
Synaptic plasticity refers to the ability of the nervous system to adapt to stimuli.24
Synaptic plasticity changes the way neurons communicate with other neurons, increasing or
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decreasing synaptic strength.25 This specifically relates to the hippocampus and the changes it
undergoes during the process of learning.24 Synaptic plasticity includes both the short- and longterm adaptations.24 Short-term synaptic plasticity refers to a rapid change, occurring within
milliseconds.26 On the contrary, long-term potentiation (LTP) can persist for upwards of a couple
of months.27
Long-term synaptic plasticity encompasses both LTP and long-term depression (LTD).
LTP refers to the increase in the strength between the pre- and post-synaptic neurons.25
Oftentimes, this is due to the activation of both the presynaptic and postsynaptic neurons within
100 ms.28 The amount of neurotransmitter released and the number of postsynaptic receptors will
increase.29 This results in long-lasting elevated levels of communication between the two
neurons, leading to changes in behavior and choices associated with memory. 25 LTD is the
opposite of LTP. It results in a decrease in the communication between two neurons.25

Figure 4 Synaptic plasticity (long-term potentiation)30
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Hippocampus
The hippocampus is composed of “the dentate gyrus, the hippocampus proper, and the
subiculum.”31 The hippocampus is located within the temporal lobe.31 It is part of the limbic
system, where behavior and emotion are regulated.32 The hippocampus is also is involved with
learning and memory.13 Learning is composed of three stages: cognitive, associative, and
autonomous. Memory is also comprised of three phases: registration, storage, and retrieval of
information.31 It is a plastic structure, meaning that it is affected by stimuli.32

Figure 5 The hippocampus33

O-GlcNAcylation
Posttranslational Modifications
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Proteins are essential to all biological processes.34 Proteins are composed of a string of
amino acids connected through peptide bonds.34 This linear strand of monomer units makes up
the primary structure of the protein.34 The spontaneous folding of proteins into α-helices and βsheets forms the secondary structure of the protein.34 The interactions of the protein side chains
promote further folding to form a 3-D structure, known as the tertiary structure.34 The specific
function of each protein is dictated by the functional groups – such as alcohols, esters, carboxylic
acids – it contains.34 The quaternary structure of the protein consists of multiple amino acid
chains connected to each other.34
The central dogma of biology states that DNA is transcribed into mRNA which then is
translated into a protein.35 After the protein is formed, it may undergo post-translational
modifications (PTM).36 Over 200 different PTMs have been identified, and these changes allow
for more variation in protein function.36 Among these, phosphorylation, acetylation,
carboxylation, methylation, and O-GlcNAcylation are just a few.36 PTMs regulate enzyme
activity, protein-protein interactions, and other processes.36

Figure 6 Levels of protein structure37

O-GlcNAcylation as a Posttranslational Modification
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O-linked N-acetylglucosaminylation (O-GlcNAcylation) is a post-translational
modification.38 An N-acetylglucosamine (GlcNAc) is added to a Serine or Threonine residue on
the protein of choice.38 O-GlcNAcylation is regulated by two enzymes: O-GlcNAc transferase
(OGT) and O-GlcNAcase (OGA).38 OGT transfers a single GlcNAc to the protein of choice,
while OGA reversibly removes GlcNAc.38 O-GlcNAcylation regulates some essential processes
in the cell.38
O-GlcNAcylation is key in epigenetics, regulating transcription, cell signaling, and
enhancing cell survival.38 Crucial transcription factors are O-GlcNAcylated to turn on the
nuclear factors of T and B lymphocytes to become active.38 O-GlcNAc is involved in gene
expression due to the interactions with transcription regulators.39 O-GlcNAcylation also plays a
role in the binding of DNA, translocation, transactivation, and the regulation of transcription
factors.38
The regulation of O-GlcNAcylation is due to a response to the availability of nutrients
and the level of cellular stress.38 A key nutrient in regulation is uridine diphosphate Nacetylglucosamine (UDP-GlcNAc), the substrate that is donated in O-GlcNAcylation.38 This
molecule is produced by the hexosamine biosynthetic pathway.38 When there is a sufficient
supply of this substrate, O-GlcNAcylation proceeds.38

Enzymes Involved in O-GlcNAcylation
The regulation of O-GlcNAcylation is managed by one pair of enzymes: OGT and
OGA.38 OGT transfers a single GlcNAc, from UDP-GlcNAc, onto the target protein.38 OGA
works in opposition to OGT, removing a single GlcNAc from the protein.38 These two enzymes
work together to maintain homeostasis.38
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Figure 7 OGA/OGT-mediated O-GlcNAcylation40
OGT has three isoforms: nucleocytoplasmic (ncOGT), mitochondrial (mOGT), and short
(sOGT).38 In the cytoplasm, both ncOGT and sOGT are present.38 In the mitochondria, mOGT is
present.38 Although they all contain a common catalytic carboxy-terminal (C-terminal) and
intervening domain (ID), they vary in length.41 The amino-terminal lobe of the catalytic domain
plays a role in the binding cleft.41 The function of the ID remains unknown.41 The difference of
the three isoforms is due to the fluctuation of the length of the amino-terminal (N-terminal)
tetratricopeptide repeats (TPRs).41 The recipient substrate is bound to OGT through interactions
with the TPR domain.41 The TPR domain mediates protein-protein interaction, and it is required
for substrate recognition.41
OGA has two isoforms: nucleocytoplasmic (ncOGA) and short (sOGA).38 ncOGA
contains an O-GlcNAc hydrolase at its N-terminal and a histone acetyltransferase-like domain at
its C-terminal.38 sOGA only contains an O-GlcNAc hydrolase as its N-terminal, and it is present
in the endoplasmic reticulum and lipid droplets.38
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O-GlcNAcylation and Diseases
The dysregulation of O-GlcNAcylation is prevalent in numerous human diseases,
including neurodegeneration, cardiovascular disease, cancer, and others.42 Due to OGlcNAcylation’s influence on neuronal development and synaptic plasticity, Alzheimer’s disease
is associated with aberrant levels of O-GlcNAcylation.42 O-GlcNAcylation acts as a protector by
inhibiting necroptosis.43 Therefore, a decrease in O-GlcNAcylation has been found in patients
with AD.43 Additionally, O-GlcNAc is present in both the protein Tau, which cause
neurofibrillary tangles when hyperphosphorylated, and amyloid precursor proteins, which are
found in neuritic plaques.44
The activity of OGT is upregulated in the heart versus other tissue.45 O-GlcNAcylation
contributes to “ischemic cardioprotection, hypertrophy, diabetic complications, hypertension,
and heart failure.”45 As a result, improper levels of O-GlcNAc can have notable implications.
Both an increase and a decrease in the levels of O-GlcNAc were shown to be associated with
heart failure.45
Cell division and metabolism are regulated by O-GlcNAcylation.42 Therefore, abnormal
levels of O-GlcNAcylation are prevalent in tumors and cancer cell lines due to its effects on
tumorigenesis and tumor metastasis.42 This is due to a decrease in the levels of O-GlcNAc as a
result of an increase in the enzymatic activity of OGA.42

GSK3
Kinases
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Protein kinases add a phosphate group to specific amino acids within a substrate.46 These
enzymes play a regulatory role in cells and modify protein function.46 The addition of the
phosphate changes the protein’s conformation by modifying the protein to a hydrophilic polar
state, rather than the original hydrophobic apolar state.47 This can either increase or decrease the
activity of the target enzyme, and it changes the protein’s interaction with other molecules.46
Adenosine triphosphate (ATP) is used by the kinases to phosphorylate other proteins through
covalent bonding.48 This process results in a phosphorylated substrate and an ADP molecule.48
Phosphorylation is involved in the regulation of cell division and growth, protein
synthesis, signal transduction, and other important cellular processes.48 Phosphorylation is a
reversible process with the protein phosphatase conducting dephosphorylation.47 The
dysregulation of phosphorylation leads to several diseases, including tumors.47 Therefore, this
process is highly regulated within the body. Most kinases are activated through
phosphorylation.48 Phosphorylation is site-specific, and it often occurs on serine and threonine
residues.48 Also, the kinase must be localized to the target substrate for phosphorylation to
proceed.48

Figure 8 Mechanism of phosphorylation and dephosphorylation
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GSK3 as a Kinase
Glycogen synthase kinase-3 (GSK3) phosphorylates over 100 substrates.49 GSK3
contains two isoforms: GSK3α and GSK3β.49 GSK3 contains two main domains: “a primedsubstrate binding domain” and “a kinase domain” to phosphorylate the bound substrate.49 Unlike
most kinases, GSK3 is innately active, and it is inhibited most frequently by serinephosphorylation.49
GSK3 is controlled through the addition of phosphate and by substrate availability, and it
is also regulated by substrate recognition. 49 The majority of GSK3 substrates must be primed
through pre-phosphorylation.49 Along with being primed, GSK3 substrates must be co-localized
with GSK3.49 The coordination of these processes and the signaling determines if and when the
substrate will be phosphorylated by GSK.49 This specificity limits the activity of GSK3.

Figure 9 GSK3 activity50

GSK3 and Diseases
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GSK3 is correlated with neurological diseases, including psychiatric illnesses. 49 GSK3 is
also associated with neurodegenerative diseases, including Alzheimer’s disease. 49 It causes
neurofibrillary tangles, a hallmark of Alzheimer’s disease.49 GSK3 contributes to the
development of the neurofibrillary tangles because it is one of the kinases that is involved in the
hyperphosphorylation of the protein tau.51

The Relationship between O-GlcNAcylation and GSK3
O-GlcNAc and kinases are shown to be competitive inhibitors for residues with serine
and threonine acceptor regions.39 This is because a few of the O-GlcNAc sites are also the sites
of phosphorylation.52 This was suggested by the increase in the level of O-GlcNAcylation due to
the inhibition of GSK3.52 Furthermore, OGT is regulated by GSK3β.53 O-phosphorylation is
regulated in a site-specific manner by O-GlcNAcylation.52 Also, it is hypothesized that if a
GlcNAc group is added to GSK3, it may change the protein’s conformation, leading to a
decrease in the phosphorylation of GSK3.54
Due to the competitive inhibition findings, there may be a link between an increase of OGlcNAcylation and the decrease of p-GSK3. Due to GSK3 being inherently on, a decrease in pGSK3 may lead to an increase in the activity of GSK3. This may allow for more phosphorylation
of the downstream targets of GSK3.
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Methodology
Genetic Model
Purpose
Gene function and gene therapy can be studied through inducible transgene expression
systems.55 The Tet-On and Tet-Off systems use tetracycline or doxycycline, its derivative, to
control gene expression.55 A few, amongst several, advantages of the tetracycline-controllable
expression system are accurate on/off regulation, specificity, and lack of cellular pathway
interference.55 The Tet-Off system uses a negative control of transgene expression while the TetOn system uses a positive control.55
This experiment used the Tet-Off system to regulate the transcription of OGA. OGA was
turned off by silencing its original gene and inserting a gene that can be externally manipulated.
The Tet-Off system used in this model resulted in the silencing of the gene used to transcribe
OGA through the administration of doxycycline. Therefore, the synthesis of OGA did not occur.
Due to OGA’s function of removing GlcNAc from proteins, the lack of performance should lead
to an increase in GlcNAc.

Figure 10 Tet-Off/Tet-On doxycycline system and gene transcription 56
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Table 1 Male Mice On/Off Doxycycline
Mouse ID On/Off Doxycycline

Table 2 Female Mice On/Off Doxycycline
Mouse ID On/Off Doxycycline

971

ON

564

ON

973

ON

969

ON

974

OFF

996

ON

977

OFF

1002

OFF

989

OFF

1003

OFF

1008

ON

1004

ON

1011

ON

1017

OFF

1022

ON

1018

OFF

1024

OFF

1021

ON

1026

OFF

1032

OFF

1027

OFF

1033

ON

1038

ON

1034

OFF

1044

OFF

1036

ON

1056

ON

1040

ON

1009

ON

1041

ON

1010

OFF

1042

OFF

1023

ON

1048

OFF

1025

OFF

1051

OFF

1030

ON

1062

ON

1043

OFF

1069

OFF

1045

OFF

1058

ON

1063

OFF
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Obtaining the Samples
The mice used in this study were identified in multiple ways. First, they were given a
number that correlated to its cage. Due to there being multiple mice in each cage, the ears of the
mice were also tagged in order to identify the mouse of interest from the other mice. An
isoflurane chamber was used to make the mouse unconscious. After this occurred, a guillotine
was used to sacrifice the mouse, and then the brain of the mouse underwent dissection over dry
ice. The cerebellum, frontal cortex, hippocampus, and excess tissue were placed in their
corresponding labeled test tubes. The test tubes were placed in liquid nitrogen for several hours
until they were transported for storage in the -80°C freezer.

Homogenizing the Samples
The samples were homogenized, and then they were stored at -20°C. Briefly, a mixture of
protease inhibitor and phosphatase inhibitor at a 1:100 ratio to tissue protein extraction reagent
was used to make the lysis buffer. A homogenizer was used to homogenize the samples. The
samples were then put on ice for 30 minutes, and then they were centrifuged at 4°C for 15
minutes at 3,200 revolutions per minute. The supernatant was stored at -20°C after the pellets
were discarded.

Western Blot
Purpose
The Western Blot technique is used to identify particular proteins within a multitude of proteins
derived from cells.57 Once identified, the concentration of the proteins within a particular tissue
sample can be determined.57 There are three steps in the Western Blot process. First, gel
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electrophoresis is used to separate the proteins by size.57 Second, the proteins are transferred onto
a polyvinylidene fluoride (PDVF) paper.57 Lastly, the PDVF paper, which now contains the
proteins, goes through a series of washes.57 A primary and secondary antibody are used to bind
to the target protein.57 The primary antibody first binds to the epitope of the protein.58 The
proteins of interest for this experiment are p-GSK3β, GSK3β, and O-GlcNAc. The secondary
antibody is designed to bind to the primary antibody. 58 The secondary antibody contains an
enzyme that produces light.58 The amount of enzyme present causes for differing amounts of
light, and this production of light can be quantified to determine the relative concentrations of the
target proteins in a given sample.58

Figure 11 Visualization of the Western Blot protocol59

Procedure
Specific Aim I
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To determine whether the ratio of p-GSK3β:GSK3β is significantly different between the control
group compared to the experimental group.

Tissue Samples Used
Mouse ID On/Off Doxycycline

Genotype

971

ON

CAMK tTA+TREOGNgk +DOX

973

ON

WT+ DOX

974

OFF

WT

977

OFF

WT

989

OFF

CAMK tTA+TREOGNgk

1008

ON

WT+ DOX

1011

ON

CAMK tTA+TREOGNgk +DOX

1022

ON

CAMK tTA+TREOGNgk +DOX

1024

OFF

CAMK tTA+TREOGNgk__

1026

OFF

CAMK tTA+TREOGNgk__

1027

OFF

WT__

1038

ON

WT +DOX

1044

OFF

CAMK tTA+TREOGNgk__

1056

ON

CAMK tTA+TREOGNgk +DOX

Table 3 Tissue samples utilized with genotype listed

Western Blot Protocol (p-GSK3β)
Preparing Samples: 2 µL of homogenate, 3.3 µL of sample buffer, and 14.7 µL of deionized
water were added to each microcentrifuge tube per tissue sample. The tube was then vortexed
and heated for 10 minutes at 70°C.
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Running the Gel: A gel of 7.5% acrylamide was made. 2 µL of standard ladder was added to the
leftmost well, and 20 µL of samples were added to the remaining wells. The gel was run in
running buffer for 40 minutes at 200 V.
Transfer: PVDF paper was washed in methanol for 10 seconds, and then it was soaked in transfer
buffer. Then, a “sandwich” was made in the order: sponge, filter paper, PVDF paper, gel, filter
paper, sponge. This was put into a chamber containing a stir bar and ice pack. The transfer ran
for one hour at 100 V in the cold room (4°C).
Wash 1: The blot was washed for 5 minutes in TBS-T.
Milk Block: The blot was blocked for 60 minutes in 5% milk with agitation while at room
temperature.
Wash 2: The blot was washed for 15 minutes in TBS-T three times.
Primary Antibody: The primary antibody solution was prepared [1:5000] using 1 µL of anti-pGSK3β and 5 mL of 5% milk. The solution was added to the blot, and it was blocked overnight
with agitation in the cold room (4°C).
Wash 3: The blot was washed for 15 minutes in TBS-T four times.
Secondary Antibody: The secondary antibody solution was prepared [1:5000] using 1 µL of antirabbit and 5 mL of 5% milk. The solution was added to the blot, and it was blocked for one hour
with agitation at room temperature.
Wash 4: The blot was washed for 15 minutes in TBS-T three times.
Developing Blot: The blot was developed for 5 minutes in a 1:1 ECL solution. Bio-Rad
Chemiluminescence Doc Imager was used to view the blot. The exposure was adjusted as
needed.
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Western Blot Protocol (GSK3β)
After p-GSK3β was detected, the PVDF blot was stripped with stripping buffer for 5 minutes.
The Western Blot Protocol was then followed starting at Wash 1. For primary antibody, the
solution was prepared [1:8000] using 1 µL of anti-GSK3β and 8 mL of 5% milk. For secondary
antibody, the solution was prepared [1:5000] using 1 µL of anti-rabbit and 5 mL of 5% milk.

Image Lab
Image Lab was used to determine the relative amount of p-GSK3β between the experimental and
the control group.

Specific Aim II
To determine whether the total level of GSK3β is significantly different between the control
group compared to the experimental group.

Western Blot Protocol (O-GlcNAc)
After GSK3β was detected, the PVDF blot was stripped with stripping buffer for 10 minutes.
The Western Blot Protocol was then followed starting at Wash 1. For primary antibody, the
solution was prepared [1:2000] using 1.5 µL of anti-O-GlcNAc and 3 mL of 5% milk. For
secondary antibody, the solution was prepared [1:5000] using 1 µL of anti-mouse and 5 mL of
5% milk.

Western Blot Protocol (Actin)
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After GSK3β was detected, the PVDF blot was stripped with stripping buffer for 10 minutes.
The Western Blot Protocol was then followed starting at Wash 1. For primary antibody, the
solution was prepared [1:5000] using 1 µL of anti-O-GlcNAc and 5 mL of 5% milk. For
secondary antibody, the solution was prepared [1:5000] using 1 µL of anti-mouse and 5 mL of
5% milk.

Image Lab
Image Lab was used to determine the relative amount of GSK3β between the experimental group
and the control group.

Data Analysis
Specific Aim I
For the first specific aim, I compared the ratio of p-GSK3β:GSK3β between the control
group, off Doxy, and the experimental group, on Doxy. Figure 12 displays the levels of pGSK3β and GSK3β for Western Blot 1. Table 3 explains the genetic makeup of the mice that
were used in this study. The top band is composed of p-GSK3β (molecular weight 47 kD), and
the bottom band is composed of GSK3β (molecular weight of 47 kD).
974

977

973

989

1024

971

p-GSK3β
(MW = 47 kD)

GSK3β
(MW = 47 kD)

Figure 12 Western Blot analysis of Blot 1 results
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Image Lab was used to calculate the amount of protein in each band. Once this
information was collected, the amount of p-GSK3β in each band was compared to the amount of
GSK3β to determine the ratio of p-GSK3β:GSK3β. The genetic makeup of each mouse was
taken into consideration when the comparison was being conducted. The four groups of genetic
makeup are: wild type (WT), wild type on doxycycline (WT + DOX), CAMK tTA+TREOGNgk
+DOX (OGA KD + DOX), and CAMK tTA+TREOGNgk (OGA KD).
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
WT

n=3

WT+DOX

CAMK tTA+TREOGNgk

CAMK tTA+TREOGNgk+DOX

Graph 1 Ratio of p-GSK3β:GSK3β
Due to the evaluation of only three successful Western Blots in this study (n=3), this
research is only considered preliminary data. This was not enough data to provide statistical
analysis.
It was expected that the ratio of p-GSK3β:GSK3β would be significantly lower in the
experimental group compared to the control group. However, the data collected for specific aim I
showed that there was no significant difference for the levels for p-GSK3β compared to GSK3β.

Specific Aim 2
For the second specific aim, I compared the amount of GSK3β relative to actin between
the control group, off Doxy, and the experimental group, on Doxy. Figure 13 displays the levels
of GSK3β and actin for Western Blot 10. As suggested before, one should refer to Table 3 to
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understand the genetic makeup of the mice that were used in this study. The top band is
composed of GSK3β (molecular weight 47 kD), and the bottom band is composed of actin
(molecular weight of 42 kD).
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Figure 13 Western Blot analysis of Blot 10 results
Image Lab was used to calculate the amount of protein in each band. Once this
information was collected, the amount of GSK3β in each band was compared to the amount of
actin to determine the relative amount of GSK3β. Again, the genetic makeup of each mouse was
taken into consideration when the comparison was being conducted.
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This research is only considered preliminary data due to the evaluation of only three
successful Western Blots in this study (n=3). Additionally, this was not enough data to provide a
statistical analysis.
It was expected that there is no significant difference of the total level of GSK3β between
the control group compared to the experimental group. The data I collected suggested that my
hypothesis was correct. Therefore, it would indicate that the level of O-GlcNAc does not affect
the synthesis of GSK3β.

Conclusion
Based on the research I gathered, the trends suggest that the levels of O-GlcNAcylation
do not affect the phosphorylation of GSK3β. Additionally, it also appeared that the synthesis of
GSK3β was not affected by the levels of O-GlcNAcylation. In order to provide a statistical
analysis, additional data would need to be collected. Although this preliminary data is significant
because indicates that O-GlcNAcylation does not have a direct effect on GSK3β in the
hippocampus, it would be beneficial for future studies to observe the effects on GSK3β’s activity
assay.

Research Limitations
My research had several limitations. The most critical drawback was the insufficient
number of Western blots performed. I was only able to conduct three successful pairs of Western
blots (in order to collect data for all of my samples, I needed to run two Western blots). This
resulted from the time it took for me to discover the correct concentrations of primary and
secondary antibodies that would result in a successful Western blot. I had many failed attempts
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due to incorrect concentrations. Statistical analysis was not able to be conducted due to the
sample size of three. Also, this study only utilized fourteen different tissues samples. The
inadequate sample size inhibits the results to be generalized.

Future Studies
Future studies should use a greater number of samples when conducting this same
experiment. This would allow for the findings to be more precise and the conclusions made from
this study would be supported or disproved by the supplementary data. Additionally, adding
female samples to the study to establish whether there are significant differences between males
and females in this study, specifically in respect to the Tet-Off system. The level of
phosphorylation of GSK3β substrates between the experimental group and the control group
should be studied. Although the potential activity of GSK3β within the hippocampus was not
affected, it would be beneficial to study the competitive inhibition between GSK3β and OGlcNAc within the hippocampus to determine if the activity assay of GSK3β is affected by the
levels of O-GlcNAc. Also, future studies should observe the relationship between OGlcNAcylation and the phosphorylation of GSK3β, as well as the activity assay of GSK3β, in
other regions of the brain.
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Appendix A: List of Abbreviations
AD – Alzheimer’s disease
ATP – adenosine trisphosphate
C-terminal – carboxy-terminal
CNS – central nervous system
GABA – gamma aminobutyric acid
GlcNAc – N-acetylglucosamine
GSK3 – glycogen synthase kinase
ID – intervening domain
LTD – long-term depression
LTP – long-term potentiation
mOGT – mitochondrial OGT
N-terminal – amino-terminal
ncOGA(T) – nucleocytoplasmic OGA(T)
OGA – O-GlcNAcase
O-GlcNAc – O-linked GlcNAc
O-GlcNAcylation – O-linked N-acetylglucosaminylation
OGA – O-GlcNAcase
OGT – O-GlcNAc transferase
p-GSK3 – phosphorylated glycogen synthase kinase
PNS – peripheral nervous system
PTM – post-translational modification
PDVF – polyvinylidene fluoride
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RMP – resting membrane potential
sOGA(T) – short OGA(T)
TPR – tetratricopeptide repeat
UDP-GlcNAc – uridine diphosphate N-acetylglucosamine
VGCaC – voltage-gated calcium channels
VGKC – voltage-gated potassium channels
VGNaC – voltage-gated sodium channels

